Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record.

A PHASE I TRIAL OF IMMUNOSUPPRESSION WITH ANTIIC AM-1 (CD54) mAb IN RENAL ALLOGRAFT RECIPIENTS

HAUG, CRAIG E., COLVIN, ROBERT B., DELMONIco, FRANCIS L., AUCHINCLOSS, HUGH, TOLKOFF-RUBIN, NINA, PREFFER, FREDERIC I., ROTHLEIN, ROBERT, NORRIS, STEVE, SCHARSCHMIDT, LINDA, COSIMI, A. BENEDICT·1993·Transplantation

Abstract

Several adhesion molecules contribute to the interaction between T cells and antigen presenting cells or target cells. Leukocyte function-associated molecule-1 (LFA-1[CD11a/CD18]) and intercellular adhesion molecule-1 (ICAM-1 [CD54]) are one such critical adhesive receptor-counter-receptor combination. The importance of ICAM-1 dependent adhesion in the rejection response was initially demonstrated in cynomolgus renal allograft recipients treated with the anti-ICAM-1 murine monoclonal antibody BIRR1. BIRR1 also appeared to limit ischemic damage in these animals. A Phase I clinical trial has subsequently been completed in 18 patients who received cadaver donor renal allografts at high risk for delayed graft function (prolonged preservation time, highly-sensitized recipient). An adequate BIRR1 serum level was associated with significantly less delayed graft function (P < .01) and rejection (P < .01). In 1-hr biopsies, mouse IgG was detected along the endothelium of the vessels and glomeruli in the graft. There were no instances of primary non-function (PNF), and current allograft survival (followup: 16-30 months) in these "high-risk" mAb-treated patients is 78%. There were 3 instances of PNF and a graft survival rate of 56% in the recipients of the contralateral kidney allografts treated with conventional immunosuppression. No significant "first-dose" effect was associated with BIRR1 administration. These results establish a dosing schedule and the clinical safety of BIRR1. They also suggest that inhibition of leukocyte adhesion by mAb therapy may be useful in controlling allograft rejection and possibly in limiting reperfusion injury. Thus, these observations support the clinical importance of accessory molecules in T cell function. We hypothesize that anti-CD54 mAb acts by blocking leukocyte adhesion to the endothelium, thereby interfering with sensitization or target cell interaction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-199304000-00016

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 293

Metadata

Authors
HAUG, C. E., COLVIN, R. B., DELMONIco, F. L., AUCHINCLOSS, H., TOLKOFF-RUBIN, N., PREFFER, F. I., ROTHLEIN, R., NORRIS, S., SCHARSCHMIDT, L., & COSIMI, A. B.
Venue
Transplantation
Published
1993-04
Volume
55
Issue
4
Pages
766-772
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2027809685
Cited by
293
References
0
FWCI
27.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A PHASE I TRIAL OF IMMUNOSUPPRESSION WITH ANTIIC AM-1 (CD54) mAb IN RENAL ALLOGRAFT RECIPIENTS. https://app.cochat.ai/papers/10.1097/00007890-199304000-00016
The paper
HAUG, C. E., COLVIN, R. B., DELMONIco, F. L., AUCHINCLOSS, H., TOLKOFF-RUBIN, N., PREFFER, F. I., ROTHLEIN, R., NORRIS, S., SCHARSCHMIDT, L., & COSIMI, A. B. (1993). A PHASE I TRIAL OF IMMUNOSUPPRESSION WITH ANTIIC AM-1 (CD54) mAb IN RENAL ALLOGRAFT RECIPIENTS. Transplantation. https://doi.org/10.1097/00007890-199304000-00016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.